


The Metabolic Syndrome, Atrial Fibrillation and Stroke: Tackling An Emerging Epidemic

Reza Hajhosseiny MBBS BSc, Gareth K. Matthews MBBS PhD, Gregory YH Lip MD FRCP DFM FACC FESC



www.elsevier.com/locate/buildenv

PII: S1547-5271(15)00812-7
DOI: <http://dx.doi.org/10.1016/j.hrthm.2015.06.038>
Reference: HRTM6337

To appear in: *Heart Rhythm*

Cite this article as: Reza Hajhosseiny MBBS BSc, Gareth K. Matthews MBBS PhD, Gregory YH Lip MD FRCP DFM FACC FESC, The Metabolic Syndrome, Atrial Fibrillation and Stroke: Tackling An Emerging Epidemic, *Heart Rhythm*, <http://dx.doi.org/10.1016/j.hrthm.2015.06.038>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The metabolic syndrome, atrial fibrillation and stroke: tackling an emerging epidemic

Short/Running Title: Metabolic syndrome, Atrial Fibrillation and Stroke

Reza Hajhosseiny MBBS BSc^{1*}, Gareth K. Matthews MBBS PhD² and Gregory YH Lip MD
FRCP DFM FACC FESC^{3,4}

¹ BHF Centre of Cardiovascular Excellence, St. Thomas' Hospital, Westminster Bridge Road,
London, SE1 7EH, UK

² Department of Physiology, Development and Neuroscience, University of Cambridge,
Downing Site, Cambridge, CB2 3EG, UK

³ University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham,
B18 7QH, UK

⁴ Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health,
Aalborg University, Aalborg, Denmark

* Corresponding author (email reza.hajhosseiny@kcl.ac.uk)

Keywords

Metabolic syndrome, Atrial fibrillation, Stroke, NOACs, Warfarin, Anticoagulation

Abbreviations

AF-Atrial Fibrillation, NOAC(s)-Non vitamin K antagonist Oral Anticoagulation drugs,
BMI-Body Mass Index, WHO-World Health Organisation, VKA-Vitamin K Antagonists,
TTR-Time in Therapeutic Range

Conflicts of interest

G.Y.H.L. declares the following: Speaker's Bureau – Bayer, BMS/Pfizer, Boehringer
Ingelheim, Daiichi Sankyo, Medtronic, Sanofi Aventis; Consultant/Advisory Boards – Bayer,
Astellas, Merck, Sanofi, BMS/Pfizer, Daiichi Sankyo, Biotronik, Medtronic, Portola,
Boehringer Ingelheim.

Download English Version:

<https://daneshyari.com/en/article/5959552>

Download Persian Version:

<https://daneshyari.com/article/5959552>

[Daneshyari.com](https://daneshyari.com)